Hematology | Phase III Developments

Akebia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference

Lead Product(s): AKB-6548

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2020

Details:

The posters present studies of Akebia's investigational oral HIF-prolyl hydroxylase inhibitor (HIF-PHI), vadadustat.

Actinium pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting

Lead Product(s): Apamistamab-I-131

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

100% of patients receiving Iomab-B achieving transplant engraftment without delay compared to 18% of patients in the control arm.

BeyondSpring

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

BeyondSpring’s Plinabulin Activates Adaptive and Innate Immune System

Lead Product(s): Plinabulin

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Presentation at the 2020 ASCO-SITC provides strong validation for Plinabulin as a potent activator of the innate immune system.

Achillion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Alexion Completes Acquisition of Achillion

Lead Product(s): Danicopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

Deal Size: $930.0 million Upfront Cash: $930.0 million

Deal Type: Acquisition January 28, 2020

Details:

Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases.

Zydus Cadila

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Zydus inks pact with China Medical System to market Desidustat in Greater China

Lead Product(s): Desidustat

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: China Medical System Holdings Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 20, 2020

Details:

Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.

Dova Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia

Lead Product(s): Avatrombopag

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Enrollment remains ongoing for the phase 3 clinical study of avatrombopag for the treatment of patients with CIT.

Akari Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study

Lead Product(s): Nomacopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

All patients treated with nomacopan achieved the primary endpoint of transfusion independence.

Samsung Bioepis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase ...

Lead Product(s): Eculizumab

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

To date, SB12 (AMT904) is the only biosimilar candidate referencing Soliris® (eculizumab) to be granted IND approval in China.

Shield Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

China licence agreement for Feraccru/Accrufer

Lead Product(s): Ferric Maltol

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical

Deal Size: $62.8 million Upfront Cash: $11.4 million

Deal Type: Licensing Agreement January 08, 2020

Details:

Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .

Apellis Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Apellis climbs as its drug beats Alexion's Soliris in phase 3

Lead Product(s): APL 2

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

In a head-to-head phase 3 trial after 16 weeks, hemoglobin levels in the pegcetacoplan arm had increased by 3.8 g/dL over the Soliris group, resulting in the trial hitting its primary endpoint.

Find

Find Hematology Drugs in Phase III Clinical Development

Phase III

A collaboration with SCORR Marketing

Product Type

Companies

Akebia Therapeutics

Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference

Actinium pharmaceuticals

Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting

BeyondSpring

BeyondSpring’s Plinabulin Activates Adaptive and Innate Immune System

Achillion

Alexion Completes Acquisition of Achillion

Zydus Cadila

Zydus inks pact with China Medical System to market Desidustat in Greater China

Dova Pharmaceuticals

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia

Akari Therapeutics

Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study

Samsung Bioepis

Samsung Bioepis and AffaMed Therapeutics’ Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase ...

Shield Therapeutics

China licence agreement for Feraccru/Accrufer

Apellis Pharmaceuticals

Apellis climbs as its drug beats Alexion's Soliris in phase 3